Global Single-Cell Omics Market 2023-2030

Global Single-Cell Omics Market 2023-2030

Global Single-cell omics Market Size, Share & Trends Analysis Report by product Type (Single-Cell Genomics, Single-Cell Transcriptomics, Single-Cell Proteomics, and Single-Cell Metabolomics), by Application (Oncology, Cell Biology, Neurology, Immunology, and Other) and by End User (Pharmaceutical & Biotechnology Companies, Academic and Research Organizations and Hospital and Diagnostic Laboratories), Forecast Period (2023-2030)

The global Single-cell omics market is anticipated to grow at a CAGR of 18.2% during the forecast period (2023-2030). The increasing adoption of the Tapestri Platform for translational research and clinical development by many cancer centers and global pharma companies demonstrates the necessity of single-cell multi-omics. Single-cell omics provides mobility solutions as they are easily accessible via most electronic devices. Single-cell omics is a rapidly growing field with applications in a wide range of biomedical research areas. As the technology becomes more accessible and affordable, it is being adopted by researchers globally.

Segmental Outlook

The global Single-cell omics market is segmented on the product type, application, and end user. Based on the product type, the market is sub-segmented into single-cell genomics, single-cell transcriptomics, single-cell proteomics, and single-cell metabolomics. Based on application, the market is sub-segmented into oncology, cell biology, neurology, immunology and other. And based on the end user, the market is sub-segmented into pharmaceutical & biotechnology companies, academic and research organizations and hospital and diagnostic laboratories. among the end user, the academic and research organizations sub-segment is anticipated to hold a considerable share of the market, owing to the spike in the number of research projects that are currently underway at private and government academic and research organizations.

The Oncology Sub-Segment is Anticipated to Hold a Considerable Share of the Global Single-cell omics Market

Among the application, the Oncology sub-segment is expected to hold a considerable share of the global Single-cell omics market. This segmental growth is attributed to several factor such as, increasing prevalence of cancer and rising applications of single-cell analysis in studying cancer progression is projected to fuel the demand for omics technology in understanding the cell biology of cancer. For instance, In June 2023, Owkin, Nanostring and world-leading cancer research institutions University of Pittsburgh, Gustave Roussy, Lausanne University Hospital, Uniklinikum Erlangen/Friedrich-Alexander-Universität Erlangen-Nürnberg, and Charité - Universitätsmedizin Berlin are launching MOSAIC (Multi Omic Spatial Atlas In Cancer) at the American Society of Clinical Oncology’s annual meeting. MOSAIC is a landmark $50 million project to revolutionize cancer research through the use of spatial omics, a set of cutting-edge technologies that offer unprecedented information on the structure of tumors.

Regional Outlook

The global Single-cell omics market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Asia pacific is anticipated to hold a prominent share of the market across the globe, owing to growing adoption of smart learning through Single-cell omics.

The North America Region is Expected to Grow at a Significant CAGR in the Global Single-cell omics Market

Among all regions, the North America regions is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to improving medical infrastructure and increasing strategic initiatives by market player for better research and product development in the regions. For instance, in April 2023, Mission Bio, Inc., the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced that it has entered into an agreement with Fulgent Genetics, a technology-based company with a well-established clinical diagnostic business and a therapeutic development business. Fulgent Genetics is now able to offer single-cell multi-omics on the Tapestri Platform on its fully customizable menu of services, including whole genome, whole exome, RNA sequencing, tumor profiling, methylation sequencing, liquid biopsy, single-cell sequencing, spatial biology, and pathology services to support its growing pharma client demands. Additionally, Fulgent Genetics will evaluate the Tapestri Platform for applications in clinical development to streamline the drug development and approval process.

Also, increasing investing activities and government initiatives in the region, are also driving the market. For instance, in November 2023, The Texas A&M University System has received a $1.19 million grant from the National Institutes of Health (NIH) for a multidisciplinary collaboration to study the intricate connections between genomics, nutrition and health. Understanding these connections will help in the diagnosis and treatment of cancer and other diseases.

Market Players Outlook

The major companies serving the Single-cell omics market include Becton, Dickinson and Company, Berkeley Lights Inc, BGI Genomics Co. Ltd, Danaher Corp, Dolomite Bio, Epicypher Inc., Fluidigm Corp, Illimina, Inc, Miltenyi Biotec B.V. & CO., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, In August 2023, Scale Biosciences, Inc. announced an expansion of their product portfolio to enable a broader range of single cell omics experiments and unlock new translational research applications. New products include the ScaleBio Single Cell Methylation Kit, ScaleBio Single Cell CRISPR Guide Enrichment Kit, Scale-plex Kit, and additional capabilities for the company’s existing ScaleBio Single Cell RNA Sequencing Kit to facilitate more diverse experimental designs and broader use of translational samples leveraging innovative, scalable, and accessible tools to democratize single cell omics across research applications without the need for additional instrumentation.

The Report Covers

Market value data analysis of 2022 and forecast to 2030.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global Single-cell omics market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market-entry and market expansion strategies.

Competitive strategies by identifying ‘who-stands-where’ in the market.